Virological and immunological study on non-A, non-B hepatitis

我们从非甲、非乙型肝炎患者的肝细胞和淋巴细胞原代培养中检测了病毒。然而，到目前为止，我们还没有找到任何负责的代理人通过这种方法。1989年，CHIRON公司的Choo等人和Kue等人成功地分离了丙型肝炎病毒基因产物，建立了丙型肝炎病毒循环抗体的检测体系。应用Ortho诊断系统公司提供的酶联免疫吸附试验试剂盒，检测了非甲、非乙型急、慢性肝病患者血清中抗丙型肝炎病毒抗体。在急性散发性非甲非乙型肝炎、输血后非甲非乙型肝炎、慢性非甲非乙型肝炎、慢性非甲非乙型肝炎、肝硬变、非甲、非乙型肝细胞癌分别有44%、62%、76%、%和70%的非甲、非乙型肝细胞癌VAS阳性，而在非甲、非乙型肝炎和肝硬变患者中，VAS抗体阳性率不到5%。15例输血后发生肝细胞癌的慢性肝炎和肝硬变患者全部抗-HCV阳性，表明丙型肝炎病毒持续感染与肝细胞癌的发生有密切关系。在干扰素治疗应答方面，非甲非乙型慢性肝炎患者血清β2微球蛋白水平较慢性乙型肝炎患者明显升高，肝内HLA1类抗原表达较慢性乙型肝炎患者弱得多。但与慢性乙型肝炎患者相比，干扰素治疗后小叶内浸润性淋巴细胞的分级下降更明显，提示非甲型、非乙型慢性肝炎患者对干扰素的治疗反应存在差异。非乙型和乙型肝炎。

We have tried to detect the virus(es) in the hepatocytes arid lymphocytes of primary culture after being obtained from patients with non-A,non-B hepatitis. However, until now we could not find any responsible agent by this method. In 1989, Choo et al and Kue et al in Chiron Co. research group diicceeded to isolate the gene product of hepatitis C virus (HCV) and established an assay system for circulating antibody to HCV. Using the ELISA test kit provided by Ortho Diagnostic System Co., iwe tested anti-HCV antibody in sera of patients with acute and chronic liver diseases of non-A,non-B type. Anti-HCV antibody vas positive in 44 % of acute sporadic non-A,non-B hepatitis, in 62 % of posttransfusion non-A,non-B hepatitis, in 76 % of chronic hepatitis of non-A,non-B type, in 64 %"of liver cirrhosis and 70 % of hepatocellular carcinoma of non-A,non-B type respectively: To the contrary, in type B hepatitis and cirrhosis, this antibody vas detected only in less than 5 %.Among the patients with non-A,non-B acute hepatitis, anti-HCV positive cases had a significantly higher tendency to chronicity as compared with anti-HCV negative cases. All 15 cases of chronic hepatitis and cirrhosis of,.posttransfusion etiology who developed finally hepatocellular carcinoma were positive for anti-HCV, indicating that there is a intimate relationship between persistent HCV infection and development of hepatocellular carcinoma.Regarding to the response to interferon administration in non-A,non-B chronic hepatitis, serum beta 2 microglobulin level was much less elevated and intrahepatic expression of HLA class 1 antigen was much weaker as compared with those in chronic hepatitis type B. However, intralobular infiltrating lymphocytes decreased much more significantly in grade after interferon administration as compared to that in chronic hepatitis of type B, suggesting that there are differences of therapeutic responses to interferon between non-A,non-B hepatitis and type B hepatitis.